Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
03 oct. 2024 08h30 HE
|
Annovis Bio, Inc.
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Annovis Bio Inc. (NYSE: ANVS) announces the availability of a broadcast titled, “Transforming Alzheimer’s Treatment: Innovative...
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
02 oct. 2024 08h30 HE
|
Annovis Bio, Inc.
NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Annovis Bio Inc. (NYSE: ANVS) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands...
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
30 sept. 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies...
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
05 sept. 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for...
Annovis Bio Reports Second Quarter Financial Results and Provides Business Update
15 août 2024 07h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for...
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
06 août 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
IBN Announces Latest Episode of The Bell2Bell Podcast Featuring Annovis Bio CEO Dr. Maria Maccecchini, Live from AAIC 2024
05 août 2024 08h00 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Aug. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is excited to announce...
Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
24 juil. 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative...
Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
16 juil. 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
09 juil. 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...